FindTrial
Sign In

DISCOntinuation VERsus continuation of antiarrhythmic drugs prior to Pulmonary Vein Isolation for atrial fibrillation and influence on dormant conduction with adenosine; a randomised controlled trial.

DISCOntinuation VERsus continuation of antiarrhythmic drugs prior to Pulmonary Vein Isolation for atrial fibrillation and influence on dormant conduction with adenosine; a randomised controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON29546
Enrollment
188
Registered
2015-09-01
Start date
2015-10-01
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation Antiarrhythmic drugs AAD Dormant conduction Pulmonary Vein Isolation PVI Catheter ablation Cryoballoon Radiofrequent Atriumfibrilleren Boezemfibrilleren Anti-aritmica

Interventions

Continuation or discontinuation of antiarrhythmic drugs 5 half lives prior to PVI

Sponsors

MST Enschede
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults with atrial fibrillation EHRA class II or higher during therapy with class I or III (excluding amiodaron) antiarrhythmic drugs eligible for PVI.

Exclusion criteria

Exclusion criteria: -Usage of amiodaron (due to very long half life time(20-100 days) these patients will be excluded) -Prior PVI or MAZE - Asthmatic condition or contra indication for adenosine -Participation in another study that is interfering with study practice

Design outcomes

Primary

MeasureTime frame
Incidence of dormant conduction with adenosine challenge after initial successful PVI.—

Secondary

MeasureTime frame
1. Incidence of AF during cessation of AAD drugs. 2. Recurrence of AF within 12 months of the procedure on ECG or >30 seconds on Holter/Vitaphone (With applied blanking period of 3 months)—

Contacts

Public ContactT. Hesselink

Medisch Spectrum Twente

t.hesselink@mst.nltel. (053) 487 2110

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)